Alkermes plc (ALKS)
| Market Cap | 5.83B +29.6% |
| Revenue (ttm) | 1.56B +3.2% |
| Net Income | 152.72M -56.7% |
| EPS | 0.91 -56.5% |
| Shares Out | 166.68M |
| PE Ratio | 38.47 |
| Forward PE | 20.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,596,630 |
| Open | 35.77 |
| Previous Close | 35.40 |
| Day's Range | 34.87 - 35.93 |
| 52-Week Range | 25.17 - 36.60 |
| Beta | 0.26 |
| Analysts | Buy |
| Price Target | 44.62 (+27.52%) |
| Earnings Date | May 5, 2026 |
About ALKS
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu... [Read more]
Financial Performance
In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price target is $44.62, which is an increase of 27.52% from the latest price.
News
Alkermes price target raised to $48 from $42 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Alkermes (ALKS) to $48 from $42 and keeps a Buy rating on the shares. Alkermes is gaining increased investor attention
Alkermes price target raised to $50 from $45 at Needham
Needham raised the firm’s price target on Alkermes (ALKS) to $50 from $45 and keeps a Buy rating on the shares after its Q1 results. The stock is up significantly
Alkermes Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth and successful integration of Avadel and LUMRYZ, with proprietary product sales up 38% year-over-year. Guidance for 2026 was raised for key metrics, and the orexin pipeline advanced in narcolepsy, IH, ADHD, and fatigue.
Alkermes reports Q1 EPS (40c) vs 13c last year
Reports Q1 revenue $392.9M, consensus $361.38M.
Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B
Sees FY26 adjusted EBITDA $370M-$410M
Alkermes plc Reports First Quarter 2026 Financial Results
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first qua...
Alkermes to Report First Quarter Financial Results on May 5, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company's first quarter...
Alkermes to present additional data from Vibrance-1 Phase 2 alixorexton study
Alkermes (ALKS) announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 at the American Academy of Neurology 2026 Annual
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the ...
Alkermes announces publication of 56-week post hoc analysis of Lybalvi
Alkermes (ALKS) announced the publication of a 56-week post hoc analysis of the effects of Lybalvi on negative symptoms in adults living with schizophrenia in the peer-reviewed publication The Journal
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of a 56-week post hoc analysis of the effects of LYBALVI® (olanzapine and samidorphan) on negative symptoms in adul...
Alkermes price target raised to $36 from $34 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Alkermes (ALKS) to $36 from $34 and keeps a Neutral rating on the shares. The firm adjusted several targets in
Alkermes price target lowered to $44 from $45 at RBC Capital
RBC Capital lowered the firm’s price target on Alkermes (ALKS) to $44 from $45 and keeps an Outperform rating on the shares as part of the firm’s broader research note
Alkermes management to meet with Piper Sandler
Meeting to be held in Chicago on April 6, Milwaukee on April 7 and in Minneapolis on April 8 hosted by Piper Sandler.
Alkermes announces initiation of Brilliance Studies
Alkermes (ALKS) announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 and
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo i...
Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
Alkermes (ALKS) rose 15% after Eli Lilly (LLY) agreed to acquire Centessa Pharmaceuticals (CNTA), reflecting renewed M&A momentum in biotech, Leerink tells investors in a research note. While the boos...
Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital
After Eli Lilly (LLY) announced the intent to acquire Centessa (CNTA) for $6.3B in cash plus an additional $1.5B split across 3 contingent value rights, RBC Capital said the deal
Alkermes jumps after Eli Lilly acquires peer Centessa
Shares of Alkermes (ALKS) ALKS) are moving higher after Eli Lilly (LLY) reached an agreement to acquire Centessa (CNTA) for up to $7.8B. Alkermes, like Centessa, is developing an orexin
Alkermes price target lowered to $43 from $45 at Piper Sandler
Piper Sandler analyst David Amsellem lowered the firm’s price target on Alkermes (ALKS) to $43 from $45 and keeps an Overweight rating on the shares. Looking further into 2026, the
Alkermes Transcript: Stifel 2026 Virtual CNS Forum
Orexin agonists are poised for a pivotal year, with competitive differentiation driven by dosing flexibility and broad applicability across sleep disorders. Clinical data support durable efficacy, and pipeline expansion targets ADHD and fatigue, while pricing strategies reflect orphan drug trends.
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 202...
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET...
Alkermes Transcript: TD Cowen 46th Annual Health Care Conference
The company has solidified its position in sleep medicine through strategic acquisitions and a robust commercial base, enabling aggressive pipeline expansion. Phase III trials for orexin agonists are underway, targeting narcolepsy and related disorders, with additional compounds advancing into ADHD and fatigue.